April 2021: Accuracy of Preimplantation Genetic Testing for Aneuploidies
Journal Club Global
One of the highest aspirations in reproductive medicine is to develop a technology allowing for identification of those embryos that have true reproductive potential. The rapid proliferation of PGT-A raises some obvious questions. Does PGT-A result in the discard of embryos with significant reproductive potential? Does the trophectoderm (TE) biopsy decrease the ability of the blastocyst to implant? The answers to these questions relate to the potential for PGT-A to improve clinical outcomes, that is, improve delivery rates, reduce multiple births, and reduce spontaneous abortion.
Hosts Dr. Kurt Barnhart, and Micah Hill will facilitate a discussion of “A multicenter, prospective, blinded, non-selection study evaluating the predictive value of an aneuploidy diagnosis using a targeted next-generation sequencing–based preimplantation genetic testing for aneuploidy assay and impact of biopsy” with authors Drs. Ashley Tiegs, Richard Scott, Emre Seli, and Chaim Jalas, along with experts Drs. David Frankfurter, Kate Devine, and Amy Sparks.
Questions and issues to be addressed during the event include:
- What is a non-selection study and what information will it provide?
- What is the difference between accuracy of a test and efficacy of an intervention?
- What is the reproductive potential of an euploid, aneuploidy and mosaic embryo?
- How can the data in this paper help to counsel patients about the safety and benefit of this targeted NGS-based PGT-A?
Richard Scott, M.D.
Ashley W. Tiegs, M.D.
David Frankfurter, M.D.
Kate Devine, M.D.
Amy Sparks, Ph.D.
Emre Seli, M.D.
Kurt Barnhart, M.D.
Micah Hill, D.O.